Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MNMD
stocks logo

MNMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.480
+17.07%
--
--
-0.446
+27.43%
--
--
-0.436
-12.8%
Estimates Revision
Stock Price
Go Up
up Image
+34.82%
In Past 3 Month
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.430
sliders
Low
18.00
Averages
28.25
High
55.00
Current: 12.430
sliders
Low
18.00
Averages
28.25
High
55.00
Canaccord
Buy
upgrade
$16 -> $25
2025-11-07
Reason
Canaccord
Price Target
$16 -> $25
2025-11-07
upgrade
Buy
Reason
Canaccord raised the firm's price target on Mind Medicine to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug potential to its model and said the company is well capitalized and significantly undervalued heading into Phase 3 data.
LifeSci Capital
Francois Brisebois
Outperform
initiated
$32
2025-10-14
Reason
LifeSci Capital
Francois Brisebois
Price Target
$32
2025-10-14
initiated
Outperform
Reason
LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine with an Outperform rating and $32 price target.
Oppenheimer
Jay Olson
Outperform
initiated
$25
2025-08-04
Reason
Oppenheimer
Jay Olson
Price Target
$25
2025-08-04
initiated
Outperform
Reason
Oppenheimer analyst Jay Olson resumed coverage of Mind Medicine with an Outperform rating and $25 price target. The firm previously had no rating on the shares. The analyst has "high conviction" that the company's lead asset MM120 will "revolutionize" neuropsychiatry with its potential to drive durable remission. MM120 has a "unique" clinical profile with its less-intense but longer psychedelic experience compared to other approaches, the analyst tells investors in a research note.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$55
2025-03-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$55
2025-03-07
Reiterates
Strong Buy
Reason
Baird
Joel Beatty
Buy
Maintains
$27 → $16
2025-03-07
Reason
Baird
Joel Beatty
Price Target
$27 → $16
2025-03-07
Maintains
Buy
Reason
Baird lowered the firm's price target on Mind Medicine to $16 from $27 and keeps an Outperform rating on the shares. The firm noted both Phase 3 trials of MM120 for GAD are enrolling witht he first results expected in the first half of 2026.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$55
2025-01-31
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$55
2025-01-31
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mind Medicine (MindMed) Inc (MNMD.O) is -6.92, compared to its 5-year average forward P/E of -6.73. For a more detailed relative valuation and DCF analysis to assess Mind Medicine (MindMed) Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.73
Current PE
-6.92
Overvalued PE
-0.54
Undervalued PE
-12.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.35
Undervalued EV/EBITDA
-37.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MNMD News & Events

Events Timeline

(ET)
2025-11-06
16:05:20
Mind Medicine Announces Q3 Earnings Per Share of 78 Cents, Exceeding Consensus Estimate of 50 Cents
select
2025-10-30 (ET)
2025-10-30
06:59:46
Mind Medicine Prices 18.375M Share Spot Secondary Offering at $12.25
select
2025-10-29 (ET)
2025-10-29
16:03:05
Mind Medicine Reveals Common Shares and Warrants Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Newsfilter
MindMed Grants 182,100 Stock Options to New Employees
  • Employee Incentive Program: MindMed has granted a total of 182,100 stock options to four newly hired non-executive employees, aiming to attract and retain talent through an appealing compensation package, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
  • Grant Details: The options have grant dates of November 17, November 24, and December 1, 2025, with an exercise price equal to the closing price on the respective grant dates, vesting over four years with 25% vesting in the first year and the remaining 75% vesting in equal monthly increments, ensuring long-term employee commitment.
  • Compliance Assurance: This option grant was approved by MindMed's Compensation Committee in accordance with NASDAQ Rule 5635(c)(4), ensuring compliance and transparency in the company's incentive measures, which enhances investor confidence.
  • Strategic Objectives: As a late-stage clinical biopharmaceutical company focused on developing novel treatments for brain health disorders, the incentive not only attracts top talent but also propels its innovation and market leadership in the brain health sector.
[object Object]
Preview
9.5
11-07NASDAQ.COM
MindMed (MNMD) Q3 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
8.5
11-03Newsfilter
Mind Medicine (MindMed) Inc. Completes Public Offering of About $259 Million, Including Full Exercise of Underwriters' Option for Extra Shares

  • Public Offering Announcement: Mind Medicine (MindMed) Inc. closed an underwritten public offering of 21,131,250 common shares at a price of $12.25 per share, raising approximately $259 million in gross proceeds.

  • Use of Proceeds: The company plans to use the net proceeds for research and development of its product candidates, working capital, and potentially for future acquisitions, although no specific plans are currently in place.

  • Management of the Offering: Jefferies, Leerink Partners, and Evercore ISI served as joint book-running managers for the offering, which closed on October 31, 2025.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and the use of proceeds, which are subject to risks and uncertainties that could affect actual results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mind Medicine (MindMed) Inc (MNMD) stock price today?

The current price of MNMD is 12.43 USD — it has increased 4.1 % in the last trading day.

arrow icon

What is Mind Medicine (MindMed) Inc (MNMD)'s business?

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

arrow icon

What is the price predicton of MNMD Stock?

Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mind Medicine (MindMed) Inc (MNMD)'s revenue for the last quarter?

Mind Medicine (MindMed) Inc revenue for the last quarter amounts to -45.67M USD, increased 84.21 % YoY.

arrow icon

What is Mind Medicine (MindMed) Inc (MNMD)'s earnings per share (EPS) for the last quarter?

Mind Medicine (MindMed) Inc. EPS for the last quarter amounts to -29567000.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Mind Medicine (MindMed) Inc (MNMD)'s fundamentals?

The market is revising No Change the revenue expectations for MNMD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 34.82%.
arrow icon

How many employees does Mind Medicine (MindMed) Inc (MNMD). have?

Mind Medicine (MindMed) Inc (MNMD) has 74 emplpoyees as of December 05 2025.

arrow icon

What is Mind Medicine (MindMed) Inc (MNMD) market cap?

Today MNMD has the market capitalization of 1.22B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free